BR112012000750A2 - "sal citrato de 9e-15-(2-pirrolidin-1-il-etóxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14.18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno" - Google Patents

"sal citrato de 9e-15-(2-pirrolidin-1-il-etóxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14.18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno"

Info

Publication number
BR112012000750A2
BR112012000750A2 BR112012000750A BR112012000750A BR112012000750A2 BR 112012000750 A2 BR112012000750 A2 BR 112012000750A2 BR 112012000750 A BR112012000750 A BR 112012000750A BR 112012000750 A BR112012000750 A BR 112012000750A BR 112012000750 A2 BR112012000750 A2 BR 112012000750A2
Authority
BR
Brazil
Prior art keywords
nonaene
hexacosa
trioxa
tetracyclo
triaza
Prior art date
Application number
BR112012000750A
Other languages
English (en)
Other versions
BR112012000750A8 (pt
BR112012000750B1 (pt
Inventor
Anthony Deodauma William
Bryan Dymock
Cheng Hsia Angeline Lee
Original Assignee
S Bio Pte Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Bio Pte Ltda filed Critical S Bio Pte Ltda
Publication of BR112012000750A2 publication Critical patent/BR112012000750A2/pt
Publication of BR112012000750A8 publication Critical patent/BR112012000750A8/pt
Publication of BR112012000750B1 publication Critical patent/BR112012000750B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112012000750-5A 2009-07-15 2010-07-14 sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo BR112012000750B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
US61/225609 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (3)

Publication Number Publication Date
BR112012000750A2 true BR112012000750A2 (pt) 2016-08-09
BR112012000750A8 BR112012000750A8 (pt) 2018-02-06
BR112012000750B1 BR112012000750B1 (pt) 2021-05-25

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000750-5A BR112012000750B1 (pt) 2009-07-15 2010-07-14 sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo

Country Status (18)

Country Link
US (1) US9062074B2 (pt)
EP (1) EP2454266B1 (pt)
JP (2) JP6013911B2 (pt)
CN (1) CN102762577B (pt)
AR (2) AR077483A1 (pt)
BR (1) BR112012000750B1 (pt)
CA (1) CA2768210C (pt)
DK (1) DK2454266T3 (pt)
ES (1) ES2429525T3 (pt)
HR (1) HRP20130941T1 (pt)
MX (1) MX2012000680A (pt)
PL (1) PL2454266T3 (pt)
PT (1) PT2454266E (pt)
RU (1) RU2543721C2 (pt)
SI (1) SI2454266T1 (pt)
SM (1) SMT201300112B (pt)
TW (1) TWI537276B (pt)
WO (1) WO2011008172A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
WO2007058627A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
ES2429525T3 (es) 2013-11-15
AR077483A1 (es) 2011-08-31
RU2012105044A (ru) 2013-08-20
US9062074B2 (en) 2015-06-23
SI2454266T1 (sl) 2013-10-30
CN102762577B (zh) 2015-01-07
HK1178159A1 (en) 2013-09-06
EP2454266B1 (en) 2013-07-10
SMT201300112B (it) 2013-11-08
PL2454266T3 (pl) 2014-01-31
CA2768210C (en) 2017-08-15
PT2454266E (pt) 2013-10-10
DK2454266T3 (da) 2013-09-08
AR114987A2 (es) 2020-11-11
BR112012000750A8 (pt) 2018-02-06
CN102762577A (zh) 2012-10-31
HRP20130941T1 (hr) 2013-11-08
TWI537276B (zh) 2016-06-11
WO2011008172A1 (en) 2011-01-20
JP6013911B2 (ja) 2016-10-25
RU2543721C2 (ru) 2015-03-10
US20120196876A1 (en) 2012-08-02
CA2768210A1 (en) 2011-01-20
EP2454266A1 (en) 2012-05-23
JP2012533539A (ja) 2012-12-27
TW201107336A (en) 2011-03-01
JP2015164941A (ja) 2015-09-17
BR112012000750B1 (pt) 2021-05-25
MX2012000680A (es) 2012-02-28

Similar Documents

Publication Publication Date Title
BRPI1011414A2 (pt) "método."
BR112012003704A2 (pt) derivados de 3-amino-5-fenil-5,6-di-hidro-2h[1,4]oxazina
BRPI1006113A2 (pt) "derivado de piridina".
GB2423375B (en) Travel assist system
BRPI1106091A2 (pt) "método de solda."
ITSA20100009U1 (it) Apparato per l'alimentazione.
BRPI0919948A2 (pt) Pirido[4,3-b]indois contendo porções rígidas
AP2012006216A0 (en) Benzimidazole-imidazole derivatives.
BRPI0917335A2 (pt) sistema de bebida de mistura posterior
AP2011005788A0 (en) Sulfonamide derivatives.
BR112012028519A2 (pt) compostos de 2,5,6,7-tetrahidro-[1,4]oxazepin-3-ilamina ou 2,3,6,7-tetrahidro-[1,4]oxazepin-5-ilamina
BRPI1014459A2 (pt) derivados de 3-(1,2,3-triazol-4-il)pirrolo[2,3-b]-piridina"
IT1400209B1 (it) " veicolo a due ruote " .
ZA201204135B (en) 3,4,4a,10b-tetrahydro-1h-thiopyrano-[4.3-c]isoquinoline derivatives
BRPI1016192A2 (pt) derivados de soxazol.
IL289379A (en) Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
FR2947939B1 (fr) Simulateur de parcours en fauteuil roulant.
BRPI1008175A2 (pt) "corpo de veículo, mais particularmente corpo de veículo terrestre"
BRPI1015089A2 (pt) nifuratel ou um sal fisiologicamente aceitável do mesmo.
FR2918802B1 (fr) Balise de detresse amelioree
EP2495517A4 (en) HELIUM RECOVERY SYSTEM
BR112012000750A2 (pt) "sal citrato de 9e-15-(2-pirrolidin-1-il-etóxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14.18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno"
IT1397021B1 (it) Carrello per rimorchi.
BRPI0917366A2 (pt) sistema de indexação.
HRP20150413T8 (xx) 11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.31.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen maleatna sol

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: S*BIO PTE LTDA (SG)

B25A Requested transfer of rights approved

Owner name: CELL THERAPEUTICS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: CTI BIOPHARMA CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/07/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF